Results 301 to 310 of about 16,343,665 (315)

Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
A series of [1-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-yl]arylhydrazones were discovered as novel inhibitors glycogen synthase kinase-3 (GSK-3). Based on initial modeling a detailed SAR was constructed. Modification of the interior binding aryl ring (Ar(1)) determined this to be a tight binding region with little room for modification. As predicted from the
Frank Preugschat, Joyce A. Boucheron, Jayme Lyn Roark Wilson, Hui-Qiang Q. Zhou, Stephen A. Thomson, Tony Y. Wang, Terrence L. Smalley, Andrew J. Peat, Scott Howard Dickerson, Stephanie L. Schweiker, Dulce Garrido, Wendy Y. Mills, Jennifer Poole Peckham   +12 more
openaire   +3 more sources

GSK-3 parameters in lymphocytes of schizophrenic patients

Psychiatry Research, 2002
Glycogen synthase kinase-3 (GSK-3) is a highly conserved serine/threonine protein kinase that is involved in the signal transduction cascades of multiple cellular processes. GSK-3 has two isoforms, designated alpha and beta. GSK-3beta protein levels and GSK-3 enzyme activity have been reported to be reduced by over 40% in postmortem frontal cortex of ...
Carmit Nadri, Nitsan Kozlovsky, Yuly Bersudsky, Galila Agam   +3 more
openaire   +3 more sources

GSK‐3: A key player in neurodegeneration and memory

IUBMB Life, 2009
AbstractAbnormalities in molecular signalling have been implicated in neurodegeneration. It is emerging that glycogen synthase kinase‐3 (GSK‐3) is a key signalling molecule that induces neurodegeneration and deficits in memory formation related to Alzheimer's disease (AD).
openaire   +3 more sources

GSK-3 is essential in the pathogenesis of Alzheimer's disease

Journal of Alzheimer's Disease, 2006
Glycogen synthase kinase-3 (GSK-3) is a pivotal molecule in the development of Alzheimer's disease (AD). GSK-3beta is involved in the formation of paired helical filament (PHF)-tau, which is an integral component of the neurofibrillary tangle (NFT) deposits that disrupt neuronal function, and a marker of neurodegeneration in AD.
openaire   +3 more sources

Novel GSK‐3 Inhibitor with Improved Cellular Activity.

ChemInform, 2004
AbstractFor Abstract see ChemInform Abstract in Full Text.
Stephen A. Thomson, Dulce Garrido, Jayme Lyn Roark Wilson, Joyce A. Boucheron, Scott Howard Dickerson, Andrew J. Peat, Stephanie L. Schweiker, Tony Y. Wang   +7 more
openaire   +4 more sources

GSK-3 as a novel prognostic indicator in leukemia

Advances in Biological Regulation, 2017
While leukemias represent a diverse set of diseases with malignant cells derived from myeloid or lymphoid origin, a common feature is the dysregulation of signal transduction pathways that influence leukemogeneisis, promote drug resistance, and favor leukemia stem cells.
openaire   +3 more sources

GSK-3: An “Ace” Among Kinases

Cancer Biotherapy and Radiopharmaceuticals
Background: Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase known to participate in the regulation of β-catenin signaling (Wnt signaling). This aids in the establishment of a multicomponent destruction complex that stimulates phosphorylation, leading to the destruction of β-catenin.
openaire   +2 more sources

GSK-3, Jack of All Trades

Science Signaling, 2008
Cross-talk between signaling pathways alters transcriptional regulatory activity of the glucocorticoid nuclear receptor.
openaire   +2 more sources

Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor

Nature Network Boston, 2004
N. Sato, L. Meijer, L. Skaltsounis, P. Greengard, A. Brivanlou   +4 more
semanticscholar   +1 more source

GSK-3 signaling in health

Advances in Biological Regulation, 2017
James A. McCubrey, Lucio Cocco
openaire   +3 more sources